PressReleases
Press Releases
Kineta Press Releases
Kineta Announces Patent Issuance for U.S. Patent Covering Composition of Matter of KCP506, a Novel Non-opioid Therapy for Chronic Pain
Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KVA12.1 Phase 1/2 clinical studies of the company’s anti-VISTA
Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506
Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506 Seattle, WA — (July 14,
Kineta’s Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA: A New Immunotherapy Approach to Treating Cancer
Kineta to Participate in “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Virtual Symposium Seattle, WA — (June
Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021 Seattle, WA —
Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR) Safety, tolerability and pharmacokinetic profile
Kineta Presenting at Multiple Investor Conferences in March 2021 Seattle, WA — (March 3, 2021) Kineta, Inc., a clinical stage
Disclaimer: The Press Releases on this page are provided for historical purposes only. The information contained in each [press release/news article/event] is accurate only as of the date each was originally issued. Kineta disavows any obligation to update the information after the date of their issuance.